Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822166 | 0.89 | MAPK14 (0.44) | ADORA1LMNAEGFR | |
| SCHEMBL6822151 | 0.86 | ADORA1 (0.54) | ADORA1IGF1RPTGDR2 | |
| SCHEMBL6821431 | 0.86 | ADORA1 (0.51) | ADORA1MAPK1IGF1RPTGDR2 | |
| SCHEMBL6821959 | 0.86 | ADORA1 (0.42) | ADORA1MAPK1IGF1RPTGER1EGFR | |
| SCHEMBL6824871 | 0.85 | NPC1 (0.38) | ADORA1BRD4PTGDR2 | |
| SCHEMBL8193833 | 0.83 | ADORA1 (0.52) | ADORA1MAPK1IGF1REGFR | |
| SCHEMBL6822534 | 0.82 | FGFR1 (0.40) | ADORA1MAPK1IGF1R | |
| SCHEMBL8809138 | 0.82 | ADORA1 (0.64) | ADORA1MAPK1IGF1RBRD4EGFR | |
| SCHEMBL6822329 | 0.82 | ADORA1 (0.41) | ADORA1MAPK1IGF1RTP53PTGER1 | |
| SCHEMBL6822330 | 0.82 | ADORA1 (0.41) | ADORA1MAPK1IGF1RLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885MAPK1 1491/4885IGF1R 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.